Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04008121 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
A Early Phase 1 study of Diabetic Retinopathy and Macular Degeneration, sponsored by MediBeacon.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04008121 is a Early Phase 1 study of Diabetic Retinopathy and Macular Degeneration that is actively recruiting participants, run by MediBeacon. The registered enrollment target is 10 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04008121, a Early Phase 1 study of Diabetic Retinopathy and Macular Degeneration, is actively recruiting participants, sponsored by MediBeacon.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fluorescein sodium and Zeiss FF450 fundus camera
- COMBINATION_PRODUCT MB-102 and Zeiss FF450 fundus camera
- COMBINATION_PRODUCT Fluorescein sodium and commercially available optical angiography imaging system
- COMBINATION_PRODUCT MB-102 and commercially available optical angiography imaging system
Study Locations (1)
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04008121
The ClinicalTrials.gov registry entry for NCT04008121 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 4 interventions - of which Fluorescein sodium and Zeiss FF450 fundus camera is the first listed.
NCT04008121 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04008121 about?
NCT04008121 is a clinical study titled "Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium". The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
What is the current status of trial NCT04008121?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-11-06. Estimated completion is 2026-12.
What conditions does trial NCT04008121 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Macular Degeneration, Retinal Vein Occlusion, Retinopathy.
What interventions are being tested in trial NCT04008121?
The interventions under investigation include: Fluorescein sodium and Zeiss FF450 fundus camera (COMBINATION_PRODUCT), MB-102 and Zeiss FF450 fundus camera (COMBINATION_PRODUCT), Fluorescein sodium and commercially available optical angiography imaging system (COMBINATION_PRODUCT), MB-102 and commercially available optical angiography imaging system (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04008121?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04008121 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photobiomodulation for the Treatment of Diabetic Macular Edema
COMPLETED · Early Phase 1
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.